Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arfolitixorin (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AGENT
  • Sponsors Isofol Medical

    • Most Recent Events

    • 05 Jul 2024 According to an Isofol Medical BA media release, an external committee of experts has performed a post hoc per-protocol analysis of the clinical phase III study AGENT that shows new results in favor of arfolitixorin. These positive data, together with conclusions from earlier studies and analyses, strengthen the outlook for the continued development of arfolitixorin.
    • 19 Mar 2024 According to an Isofol Medical BA media release, company's collaboration partner, Solasia, has confirmed its continued strong commitment in development of arfolitixorin. Isofol is presenting its strategy and a clinical development plan for the continued development of its drug candidate arfolitixorin arfolitixorin in an Investor meeting on Mar 19, 2024.
    • 04 Jul 2023 Results presented in the Isofol Medical AB Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top